- Home
- WHWK vs CHRS Comparison
WHWK vs CHRS Comparison
Compare WHWK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | CHRS |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4M | 209.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | WHWK | CHRS |
|---|---|---|
| Price | $3.75 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $7.50 | $5.51 |
| AVG Volume (30 Days) | 641.0K | ★ 940.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $0.81 |
| 52 Week High | $5.50 | $2.62 |
Technical Indicators
Market Signals| Indicator | WHWK | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 44.08 |
| Support Level | $3.70 | $1.38 |
| Resistance Level | $3.79 | $1.76 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.79 | 17.14 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.